Aberrant Wnt signaling, mainly through mutations of APC and in some cases of CTNNB1 or AXIN2, has been found in the majority of colorectal cancers. Recently, frequent promoter hypermethylation was identified to cause silencing of the secreted frizzled-related protein (sFRP) family in colorectal cancer. Restoration of sFRP in colorectal cancer cells attenuates Wnt signaling even in the presence of downstream mutations. Here we show that Wnt inhibitory factor-1 (WIF-1), a different secreted antagonist of Wnt signaling, is also silenced by promoter hypermethylation in colorectal cancer cells. Restoration of WIF-1 function, Wnt-1 siRNA, or a monoclonal antiWnt-1 antibody that we developed attenuates Wnt-1 signaling and induces significant apoptosis in these cells containing downstream mutations and expressing Wnt-1. In addition, this monoclonal anti-Wnt-1 antibody showed synergistic effects with docetaxel in treating these colorectal cancer cells and great efficacy in treating primary colorectal cancer cultures freshly prepared from patients. Therefore, our data support the hypothesis that constitutive Wnt signaling may be required to complement downstream mutations in the evolution of colorectal cancer. Furthermore, our results suggest that blockade of the Wnt signal may have a therapeutic role in the treatment of colorectal cancer.
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The activation of the canonical pathway involves activation of Dishevelled (Dvl), stabilization and accumulation of b-catenin in the nucleus, and activation of b-catenin/T-cell factor (Tcf) complex to regulate transcription of downstream target genes for cell proliferation and differentiation (Giles et al., 2003; Taketo, 2004) . In contrast, noncanonical signaling pathways do not require b-catenin, and they signal through other mediators, such as JNK, G proteins, or calcium flux (Veeman et al., 2003) . A number of Wnt antagonists have been reported to interfere with ligand-receptor interactions (Kawano and Kypta, 2003) . For example, the secreted Frizzled-related protein (sFRP) family and Wnt inhibitory factor-1 (WIF-1) directly bind to Wnt ligands. The Dickkopf (Dkk) family binds to a subunit of the Wnt receptor complex: LDL-receptor-related protein 5/6 (LRP5/6).
Colorectal cancer killed over 50 000 people in the US in 2003 alone and is expected to kill a similar number of people in 2004, according to the estimate of the American Cancer Society (www.cancer.org). The most common cause of colorectal cancer (greater than 90%) is an activating mutation in the canonical Wnt signaling pathway (Giles et al., 2003; Taketo, 2004) . A majority of the mutations was found in APC, CTNNB1, and AXIN Morin et al., 1997; Liu et al., 2000; Fodde et al., 2001) . These mutations were thought to cause constitutive downstream signaling independent of upstream signals. Recently, however, involvement of upstream signal regulation in colorectal cancer has been reported, suggesting that the Wnt signaling may be regulated in a quantitative manner at different levels (Suzuki et al., 2002 (Suzuki et al., , 2004 Caldwell et al, 2004) . For example, loss of sFRP family expression was associated with promoter hypermethylation in colorectal cancer (Suzuki et al., 2002; Caldwell et al, 2004) . Furthermore, restoration of sFRPs in colon cancer cell lines carrying CTNNB1 or APC mutations resulted in suppression of Wnt-dependent transcription and a higher rate of apoptosis, and overexpression of a Wnt-1 transgene in the b-catenin mutant cell line resulted in increased Wntdependent transcription (Suzuki et al., 2004) .
To understand further the role of upstream Wnt-1 signaling regulation in human colorectal cancer, we first examined the Wnt-1 expression at the protein level using a monoclonal anti-Wnt-1 antibody that we recently developed in colorectal cancer cell lines: SW480 and HCT116 (containing mutations in APC and CTNNB1, respectively) Morin et al., 1997) . We found overexpression of the Wnt-1 protein in both cell lines examined (Figure 1a ). This result suggests that the Wnt-1 protein level is consistent with its mRNA level studied previously in these colorectal cancer cells (Dimitriadis et al., 2001; Holcombe et al., 2002; Suzuki et al., 2004) . In contrast, no noticeable Wnt-1 expression was detected in a normal colon cell line (Figure 1a) .
Like the sFRPs, WIF-1 is one of the secreted Wnt antagonists. However, it does not share any sequence similarities with the cysteine-rich domain (CRD) of the sFRPs (Kawano and Kypta, 2003) . Instead, WIF-1 contains a WIF domain and five epidermal growth factor (EGF)-like repeats (Lin et al., 1997; Hsieh et al., 1999) . Recently, downregulation of WIF-1 in cancer has been observed (Heighway et al., 2002; Wissmann et al., 2003) . More recently, we reported correlation of promoter hypermethylation with silencing of WIF-1 expression in human lung cancer . To examine the involvement of WIF-1 in upstream signaling regulation in colorectal cancer, we analysed WIF-1 expression and methylation status of the WIF-1 promoter in colorectal cell lines. WIF-1 expression was observed in the normal colon cells, but it was missing in HCT116 cells and dramatically underexpressed in SW480 cells (Figure 1b) . Hypermethylation of the WIF-1 promoter was found in both HCT116 and SW480 cells by using methylation-specific PCR (MSP) ( Figure 1c ). In contrast, no methylation was seen in the normal colon cells expressing WIF-1. These data suggest that the status of WIF-1 expression correlates with that of its promoter methylation in colorectal cell lines. We propose that downregulation of WIF-1 occurs in colorectal cancer through an epigenetic regulation as previously reported for sFRPs (Suzuki et al., 2002; Caldwell et al, 2004; Suzuki et al., 2004) . Our finding of WIF-1 silencing by promoter hypermethylation provides more evidence that upstream Wnt signaling may be important during the development of colorectal cancer. In addition, we found that either expression of WIF-1 or transfection of Wnt-1 siRNA (at 100 nM) (Elbashir et al., 2002; He et al., 2004) induced significant apoptosis in colorectal cancer cells containing downstream mutations (Figure 1d ) (Po0.01). These results are consistent with the hypothesis that upregulation of the Wnt-1 protein in colorectal cancer cells carrying downstream mutations may still be functional as a survival mechanism by inhibiting normal apoptotic machinery (Suzuki et al., 2004) .
We have recently developed a monoclonal antibody against human Wnt-1 and reported that this antibody inhibits Wnt-1 signaling and induces apoptosis in human cancer cells expressing Wnt-1 protein, including lung and breast cancer . Next, we examined whether this monoclonal anti-Wnt-1 antibody could downregulate Wnt-1 signaling and induce apoptosis in the colorectal cancer cells. After about 5-day incubation with this monoclonal antibody (at 10 mg/ml), we found significant cell death (Figure 2a ). We saw no noticeable effect, however, in normal colon cells lacking Wnt-1 expression after the monoclonal anti-Wnt-1 antibody treatment (Figure 2a) . The cell killing effect was largely due to induction of apoptosis (Figure 2b) . Suppression of Wnt-1 signaling in these cell lines was confirmed by analysing the expression of Wnt-1 signaling mediators, such as cytosolic b-catenin (Figure 2c) . Consistent with the apoptosis induction, we detected increased level of the cleaved (active) form of caspase-3 and cytochrome c in the cytosol in these cells after the monoclonal anti-Wnt-1 antibody treatment (Figure 2c) . Survivin, an apoptosis inhibitor and a Wnt downstream , and cultured in RPMI 1640 supplemented with 10% fetal bovine serum, penicillin (100 IU/ml), and streptomycin (100 mg/ml) at 37 o C in a humid incubator with 5% CO 2 . The mouse monoclonal anti-Wnt-1 antibody (IgG 1 ) was described previously . Anti-b-actin antibody was purchased from SigmaAldrich Corp. (St Louis, MS, USA). b-Actin was used as loading control. Whole-cell extract was prepared and used in the blot. (b) RT-PCR analysis of WIF-1 expression in cell lines. The fragment of WIF-1 cDNA amplified was 188 bp. GAPDH was used as an internal control. Total RNA from cell lines was isolated and RT-PCR was performed as described previously . Primer sequences for amplifying the human WIF-1 cDNA were described previously . (c) MSP analysis of the WIF-1 promoter in cell lines. Bands in lanes labeled 'U' are unmethylated DNA products amplified with unmethylationspecific primers. Bands in lanes labeled 'M' are methylated DNA products amplified with methylation-specific primers. Bisulfite treatment of genomic DNA and PCR amplification were performed as described previously (He et al., 2003) . Sequences of the unmethylation-specific and methylation-specific primers were described previously . (d) Induction of apoptosis by transfection of Wnt-1 siRNA or expressing WIF-1 in SW480 cells. Cells were harvested 4-5 days after transfection of either WIF-1 cDNA construct or Wnt-1 siRNA by trypsinization and stained using an Annexin V FITC Apoptosis Detection Kit (Oncogene, Cambridge, MA, USA), according to the manufacturer's protocol. Then, stained cells were immediately analysed by flow cytometry (FACScan; Decton Dickinson, Franklin Lake, NJ, USA). siRNA transfection was performed according to the manufacturer's protocol (Elbashir et al., 2002) . The ion-exchange HPLC-purified siRNAs (Wnt-1 siRNA and nonsilencing siRNA control, >97% pure) were purchased from Qiagen-Xeragon (Germantown, MD, USA). The Wnt-1 siRNA targets human Wnt-1 mRNA sequence 5 0 -GGTTCCATCGAATCCTGCA-3 0 . The lyophilized siRNAs were dissolved in annealing buffer and reheated to 951C for 1 min followed by 1 h incubation at 371C. Concentration of both control and Wnt-1 siRNA used is 100 nM. The results (percentage of apoptotic cells) are the means7s.d. (error bars). Experiments were performed in triplicate and a total of 20 000 cells were analysed in each individual experiment Blockade of Wnt-1 signal in human colorectal cancer B He et al target gene (Kim et al., 2003) , was also downregulated (Figure 2c ). This result is consistent with our finding of significant reduction in TCF-dependent transcriptional activity (TOPFLASH assay) (Figure 2d ) (Po0.005) after the antibody treatment in these colorectal cancer cells. To address the question whether the anti-Wnt-1 antibody crossreacts with other Wnt family proteins, such as Wnt-2, which is known to be involved in colorectal cancer (Smith et al., 1999) , we used the antibody to treat a non-small cell lung cancer cell line A549, which expresses Wnt-2 but not Wnt-1 (Figure 2e ). We found that the anti-Wnt-1 antibody had no noticeable effect on the growth of A549 cells (Figure 2e ). An anti-Wnt-2 antibody that we developed , however, killed the A549 cells dramatically (Figure 2e ). In addition, we found that the anti-Wnt-1 antibody precipitated Wnt-1 proteins in C57Wnt-1 cells , but it did not precipitate Wnt-2 proteins in C57Wnt-2 cells or Wnt-3 proteins in C57Wnt-3 cells (data not shown). Therefore, the antiWnt-1 antibody used does not appear to crossreact with other Wnt proteins, such as Wnt-2. Taken together, these data support that Wnt signaling can still be functional at the ligand level in the presence of downstream mutations, and that Wnt signaling can be regulated at many levels.
Docetaxel has been widely studied in colorectal cancer in both preclinical and clinical studies. Although docetaxel appears to be disappointing in clinical trials (Sternberg et al., 1994; Clark et al., 1998) , it shows encouraging antitumor activity against colorectal cancer cell lines in vitro and in murine tumor models (Bissery et al., 1991; Karantanis et al., 1994; Dunne et al., 2004) . Because docetaxel is a mitotic spindle poison that inhibits depolymerization of microtubules and Wnt has also been shown to control microtubule stability (Ciani et al., 2004) , we hypothesize that Wnt blockade and docetaxel may have a synergistic effect when used together in colorectal cancer cell lines. We then treated SW480 cells with low-dose monoclonal anti-Wnt-1 antibody (2 mg/ml) and low-dose docetaxel (0.01 nM). A synergistic effect was seen starting after 48 h of treatment with the combination when compared to the antibody or docetaxel treatment alone (Figure 3 ). This interesting result argues that Wnt blockade (e.g. monoclonal anti-Wnt antibody therapy) may be able to sensitize colorectal cancer cells to docetaxel treatment.
Finally, we examined primary tissue samples freshly made from advanced colorectal cancer patients. Overexpression of the Wnt-1 protein was observed in 85.7% (six of seven) of the tissue samples examined (Figure 4a) . WIF-1 expression was missing or downregulated in Figure 2 Inhibition of Wnt-1 signaling and induction of apoptosis by a monoclonal anti-Wnt-1 antibody in human colorectal cancer cell lines. (a) Crystal violet (0.5%) staining of normal colon epithelial cells, and SW480 and HCT116 cells after the antibody treatment (about 5 days after treatment). Cells were plated in sixor 24-well plates 1 day before antibody treatment. Then, normal media were replaced by media containing antibodies and the cells were incubated at 371C in a humid incubator with 5% CO 2 . At various time points, the cells were collected using standard protocols for further analysis. Concentration of both control and anti-Wnt-1 monoclonal antibodies used is 10 mg/ml. The control monoclonal antibody used in all experiments was the same subtype as the monoclonal anti-Wnt-1 antibody (IgG 1 ). (b) Apoptosis analysis by flow cytometry (Annexin V (FL1-H; X-axis) and PI (FL3-H; Y-axis) staining) after the monoclonal anti-Wnt-1 antibody treatment (10 mg/ml for 4 days) in SW480 cells. Experiments were performed in triplicate and a total of 20 000 cells were analysed in each individual experiment. (c) Western analysis after the monoclonal anti-Wnt-1 antibody treatment (10 mg/ml for 3 days) in SW480 cells. b-Actin served as loading control. Antisurvivin antibody was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-caspase-3 antibody was purchased from Oncogene (Cambridge, MA, USA). Anti-b-catenin antibody was purchased from Transduction Laboratories (Lexington, KY, USA). Anti-cytochrome c antibody was purchased from BD Biosciences (San Diego, CA, USA). Cytosolic extracts were prepared and examined as described previously . (d) TOPFLASH assay of Tcf-dependent transcriptional activity in SW480 cells after the monoclonal anti-Wnt-1 antibody treatment (10 mg/ml for 3 days). The results are means7s.d. (error bars). Cells were plated in six-well plates. The TOPFLASH or FOPFLASH reporter plasmid was transfected transiently into cells as described previously . Tcf-mediated gene transcription was determined by the ratio of pTOPFLASH : pFOPFLASH luciferase activity, each normalized to luciferase activities of the pRL-TK reporter (cotransfected internal control). Experiments were performed in triplicate. (e) Specificity of the monoclonal anti-Wnt-1 antibody. Western analysis was used to examine Wnt-1 and Wnt-2 expressions in a non-small cell lung cancer (NSCLC) cell line A549. The mouse monoclonal anti-Wnt-2 antibody (IgG 1 ) was described previously . A549 cells were stained with 0.5% crystal violet about 5 days after the monoclonal antibody treatments as described in panel 2a legend
Blockade of Wnt-1 signal in human colorectal cancer B He et al 71.4% (five of seven) of the samples, correlating with methylation status of the WIF-1 promoter except for case 3 (Figure 4b and c). Our interpretation for case 3 is that missing of the WIF-1 transcript may be caused by other genetic abnormalities. Therefore, these results from primary colorectal cancer tissue samples appear consistent with our findings obtained from colorectal cell lines, further supporting the hypothesis that upstream Wnt signaling may be important during the development of colorectal cancer. Furthermore, to evaluate the potential therapeutic role of the monoclonal Wnt-1 antibody in the treatment of colorectal cancer, we treated these seven primary cultures freshly made from colorectal cancer patients with the antibody (at 10 mg/ml). We observed dramatic cell lysis (over 90%) in six primary cultures expressing Wnt-1 proteins approximately 6 days after the antibody treatment ( Figure 4d ). Consistently, one primary culture (case 4) lacking Wnt-1 expression was not affected by the antibody treatment (Figure 4d ), providing more evidence about the specificity of the anti-Wnt-1 antibody. Taken together, our findings suggest that monoclonal antibody blockade of Wnt signaling may have therapeutic role in the treatment of colorectal cancer, even in the presence of Wnt downstream mutations. figure) were used in the following experiments. They were cut into small pieces (1-2 mm in diameter), and digested with collagenase A (Roche Applied Science, Indianapolis, IN, USA) at room temperature for 2 h according to the manufacturer's protocol. Single cells from the digestion were stained and the cell pellets were washed twice using RPMI 1640 supplemented with 10% fetal bovine serum, penicillin (100 IU/ml), and streptomycin (100 mg/ml). Then, the cells were resuspended in the same medium and cultured in six-well plates at 371C in a humid incubator with 5% CO 2 until they were ready for the experiments. Normal colon cells (N) were used as references in the following experiments. (a) The Wnt-1 expression in primary colorectal cancer tissue samples. Western analysis was performed as described in Figure 1a legend. (b) The WIF-1 expression in primary colorectal cancer tissue samples. RT-PCR analysis was performed as described in Figure 1b legend. (c) Methylation analysis of the WIF-1 promoter in primary colorectal cancer tissue samples. MSP analysis was performed as described in Figure 1c legend. (d) Crystal violet (0.5%) staining of the primary cultured cells after the monoclonal anti-Wnt-1 antibody treatment for about 6 days. Concentration of both control and anti-Wnt-1 antibodies used is 10 mg/ml
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